Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 1/2011

01-07-2011 | Gynecologic Oncology

Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

Authors: N. Hatam, N. Ahmadloo, A. Ahmad Kia Daliri, P. Bastani, M. Askarian

Published in: Archives of Gynecology and Obstetrics | Issue 1/2011

Login to get access

Abstract

Objectives

The aim of this study was to compare two regimens of chemotherapy in patients with breast cancer, including FAC (doxorubicin, cyclophosphamide, and 5-fluorouracil) and TAC (docetaxel, doxorubicin and cyclophosphamide); and analyze the toxicity of these treatments and observe patient’s health-related quality of life.

Methods

Health-related quality of life was assessed for up to 4 months (from the beginning to the end of chemotherapy cycles), using European organization and cancer treatment quality of life questionnaire (EORTC) QLQ-C30. A group of 100 patients, with node-positive breast cancer were studied in order to compare the toxicity of adjuvant therapy TAC with FAC and the subsequent effects on the patient’s quality of life.

Results

After a 4-month follow-up of patients, our findings showed that despite having the same mean score of QOL at the start of adjuvant chemotherapy, the QOL in TAC arm was decreased more as a result of the higher range of toxicity in TAC regimen.

Conclusion

In spite of increase in disease-free patients who received TAC regimen and increase their survival rate, there is significant toxicity and decrease in QOL in TAC protocol compare to FAC protocol. Using prophylactic granulocyte colony stimulating factor (G-CSF) along with increased education aimed at improving patient’s knowledge and also the provision of a supportive group involving psychiatrics and patients that have successfully experienced the same treatment may be helpful.
Literature
1.
Micheli A, Goeberg JW, Mugno E et al (2003) European health systems and cancer care. Ann Oncol 14:41–60CrossRef
2.
3.
Brinton L, Lacey J, Devesa SS (2002) Epidemiology of breast cancer. In: Donegan WL, Spratt JS (eds) Cancer of the breast, vol 2, 5th edn. WB Saunders, Philadelphia, pp 111–132
4.
Mant D, Vessey MP (1991) Epidemiology of breast cancer. In: Kirby I, Copeland EM (eds) The breast: comprehensive management of benign and malignant diseases, vol 116. WB Saunders, Philadelphia, pp 363–365
5.
Hajian S, Mirzai Najm Abadi KH, Keramat A et al (1998) Systematic survey on the effects of limb relaxation and directed intellectual on pain and distress reduction because of the treatment’s side effects on women suffering from breast cancer during 1998–2007 in Farsi. Iran’s Breast Dis 1(3):32–43
6.
Tirgiri B, Aghebati N, Fazwl A et al (1996) Investigating the relationship between the type of adjuvant therapy with the anxiety, depression and fatigue score in breast cancer patients in Farsi. Razi Fac Nurs Obstet Mag 6:52–59
7.
Bonneterre J, Bercez C, Bonneterre M-E, Lenne X, Dervaux B (2005) Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study). Ann Oncol 16(6):915–922PubMedCrossRef
8.
Martin M (2006) Docetaxel doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Womens Health (Lond Engl) 2(4):527–37
9.
Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17(8):1205–1212
10.
Fayers PM, Aaronson NK, Bjordal K et al (2001) On behalf of the EORTC quality of life group. EORTC QLQ-C30 scoring manual (3rd edn), EORTC, Brussels
11.
Montazeri A, Harirchi I, Vahdani M (1999) The European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version. Support Care Cancer 7:400–406PubMedCrossRef
12.
Haji Mohamadi M, Ebrahimi M, Jarvandi S et al (2000) The EORTC breast cancer specific quality of life questionnaire (EORTC–BR23): translation and validation study of the Iranian version. Qual Life Res 9(2):177–184CrossRef
13.
Shaban M, Monjamed Z, Mehran A, Hassan Poor Dehkordi A (1383) The relationship between cancer’s characteristics and patients’ quality of life who treating with chemotherapy in Farsi. Haiat 22:79–84
14.
Rom J, von Minckwitz G, Eiermann W, Sievert M, Schlehe B et al (2008) Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Ann Oncol 19:1698–1705PubMedCrossRef
15.
Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRef
16.
Boer K, Lang I, Juhos É, Pinter T et al (2003) Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC)—a Hungarian experience in the BCIRG 001 trial. Pathol Oncol Res 9(3):229–238CrossRef
17.
Martin M, Liuch A, Segul MA et al (2006) Toxicity and health related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC). Ann Oncol 17(8):1205–1212PubMedCrossRef
18.
Brain GC, Bachelot T, Serin D, Kirscher S, for the RAPP-01 Trial Investigators et al (2005) Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 293:2367–2371PubMedCrossRef
19.
20.
Martin M, Pienkowsk T, Mackey J, Pawlicki M et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Eng J Med 352(22):2302–2313, 2346–2348
21.
22.
23.
24.
25.
Martin M, Vogal C, Crown J, Mackey J (2005) Life-threatening complications from doxorubicin–docetaxel chemotherapy for breast cancer. JAMA 294(17):2166
Metadata
Title
Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
Authors
N. Hatam
N. Ahmadloo
A. Ahmad Kia Daliri
P. Bastani
M. Askarian
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 1/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1609-8

Other articles of this Issue 1/2011

Archives of Gynecology and Obstetrics 1/2011 Go to the issue

General Gynecology

Effects of lumbar lordosis and pelvic inlet orientation on the outcome of the transobturator tape sling operation in women

General Gynecology

Attitudes of graduating medical doctors toward using sex selection techniques in Jordan in 2009

Materno-fetal Medicine

Assessment of placental blood flow between 22 and 34 weeks of gestation by 3D-sonography power Doppler vascular indices

Materno-Fetal Medicine

Evaluation of placental maturity by the sonographic textures

Letter to the Editor

An evolutionary insight into mutation of ATPase6 gene in primary ovarian insufficiency

Gynecologic Oncology

Epidemiology of vulvar and vaginal cancer in Germany